A B S T R A C T Highly purified inhibitor of the first component of complement (C1INH) was shown to inhibit the capacity of active Hageman factor fragments to initiate kinin generation, fibrinolysis, and coagulation. The inhibition of prealbumin Hageman factor fragments observed was dependent upon the time of interaction of the fragments with C1INH and not to an effect upon kallikrein or plasmin generated. The inhibition of the coagulant activity of the intermediate sized Hageman factor fragm.ent by C1INH was not due to an effect on PTA or other clotting factors. The inhibition by C1INH of both the prealbumin and intermediate sized Hageman factor fragments occurred in a dose response fashion. The C1INH did not appear to be consumed when the activity of the Hageman factor fragments was blocked, although the fragments themselves could no longer be recovered functionally or as a protein on alkaline disc gel electrophoretic analysis. These results suggest that the C1INH may have an enzymatic effect on the fragments or that an additional site on C1INH is involved in Cl inactivation.
INTRODUCTION
The activation of Hageman factor results in the initiation of coagulation (1), kinin generation (2, 3) , and fibrinolysis (4, 5) by activation of pre-plasma thrombo- plastin antecedent (pre-PTA)1" (1), prekallikrein (6) , and plasminogen proactivator (7, 8) . These three plasma proenzyme substrates are activated both by intact activated Hageman factor and by fragments present in serum or derived from activated intact Hageman factor experimentally (6, 9) . The inhibitor of the first component of complement (C1INH) is recognized to inhibit kallikrein (10) (11) (12) , plasmin (11) , PTA (13) , and the coagulant activity of activated Hageman factor (13) . An additional critical site by which C1INH regulates these effector systems of tissue injury is shown to be its capacity to inhibit the action of the Hageman factor fragments upon each of these three plasma proenzymes.
METHODS
Antisera to al antitrypsin and a2 macroglobulin (a2M) (Behring Diagnostics Inc., Woodbury, N. Y.); hexadimethrine bromide (polybrene) (Aldrich Chemical Co., Inc., Milwaukee, Wis.); enzodiffusion fibrin plates and streptokinase (Hyland Div., Travenol Laboratories, Inc., Costa Mesa, Calif.) were obtained as indicated. Hageman factordeficient plasma and PTA-deficient plasma were supplied by Sera-Tec Biologicals, New Brunswick, N. J. Concentration of various chromatographic fractions was performed by ultra filtration using UM-10 membranes (Amicon Corp., Lexington, Mass.) in either 500 ml, 50 ml, or Plasma was prepared for the isolation of plasma proenzymes and C1INH in ethylenediaminetetraacetic acid (ED-TA) and polybrene as described (6) . The conversion of pre-PTA (1), prekallikrein (6) , and plasminogen proactivator (7, 8) by the Hageman factor fragments was measured in terms of subsequent coagulation, bradykinin formation, and fibrinolysis. The coagulant activity of the Hageman factor fragment was determined by preparing two-fold falling dilutions of the preparation of Hageman factor fragment and relating its concentration to the partial thromboplastin time (PTT) achieved with Hageman factordeficient plasma (Fig. 1) .
Hageman factor prealbumin fragments were prepared as follows: plasma dialyzed against 0.0035 M phosphate buffer pH 8.0 containing 0.06 M NaCl was applied to Quartenary aminoethyl (QAE) Sephadex (5 X 100 cm) equilibrated with 0.0035 M phosphate buffer pH 8.0. The column was batch eluted with the dialysis buffer, concentrated to the starting volume, activated by stirring in a glass beaker for 24 h at 4VC, dialyzed against 0.0035 M phosphate buffer pH 8.0, and rechromatographed on QAE Sephadex with a linear salt gradient of 2,500 ml of dialysis buffer and 2,500 ml of 0.0035 M phosphate buffer pH 8.0 containing 0.3 M NaCl. The column was run at 50 ml/h and 12 ml fractions were collected. The Hageman factor fragments eluted between 0.23 and 0.28 M NaCl, were concentrated to 4 ml, and were fractionated at 30 ml/h on Sephadex G-100 (5 X 100 cm) equilibrated with 0.0035 M phosphate buffer pH 8.0 containing 0.15 M NaCl. The Hageman factor prealbumin fragments eluted at a mol wt of 32,500, were concentrated to approximately 20- Plasminogen was prepared by affinity chromatography of 100 ml of plasma utilizing lysine-sepharose columns and e-aminocaproic acid elution (8, 15 6 .0, and applied to Sulphoethyl (SE) Sephadex (3.5 X 30 cm) equilibrated with the dialysis buffer. The plasminogen proactivator was eluted with a linear salt gradient of 2,000 ml of equilibrating buffer and 2,000 ml of equilibrating buffer containing 0.35 M NaCl. The column was run at 50 ml/h and 10 ml fractions were collected. The plasminogen proactivator eluted between 0.12 and 0.14 M NaCl and was pooled, concentrated to 25 ml, and fractionated on Sephadex G-150 (2.5 X 150 cm) equilibrated in 0.0035 M phosphate buffer pH 8.0 containing 0.15 M NaCl. Fractionation was performed by upward flow at 10 ml/h and 2.5 ml fractions were collected. The plasminogen proactivator eluted at a mol wt of approximately 100,000 and was pooled, concentrated to 10 ml and stored at -70°C. buffer and eluted with a linear salt gradient of equilibrating buffer and 2,500 ml of 0.0035 M buffer pH 7.8 containing 0.3 M NaCl. The c run at 50 ml/h and 10 ml fractions were col C1INH was assayed functionally in microtiter C1INH peak eluted at 0.15 M NaCl (Fig. 2 Fig. 3 . The fractions containing C1INH were concentrated to 2.0 ml and further fractionated by Sephadex G-150 (2.5 X 150 cm) gel filtration equilibrated in 0.0035 M phosphate buffer pH 7.8 containing 0.15 M NaCl. Fractionation was performed by upward flow at 10 ml/h and 2.5 ml fractions were collected. No optical density at 280 nm was observed; fractions containing CIJNH eluted at 55% of bed volume and were pooled (total volume 27 ml) and stored at -70'C for further studies. This preparation had no detectable al antitrypsin or a2M as assessed by Ouchterlony analysis or electroimmunodiffusion utilizing monospecific antisera to each. This highly purified C1INH preparation (6,000 U/ml) gave a double band on alkaline disc gel electrophoresis in a region from which unstained gels yielded active C1INH upon elution (Fig. 4) .
The C1INH was assessed functionally by its ability to inhibit the hemolytic activity of erythrocyte bound C1 (EAC1) by either microtiter plate or tube titrations (16) as indicated and was quantitated by immunodiffusion (17, 18) . The titer of 1,613 U/flg of C1INH obtained is comparable to the activity in normal serum.
RESULTS
Inhibition of the action of Hageman factor fragments upon prekallikrein, plasminogen proactivator, and pre-PTA Prekallikrein. 10 Al of Hageman factor fragments were incubated with increasing volumes of highly purified C1INH (1,000 U/ml) at 37°C for 30 min. Each mixture was brought to a final volume of 160 Al and incubated for 2 min at 37°C with fresh human plasma as a source of prekallikrein and kininogen, and the bradykinin generated was determined. As illustrated in Fig. 5 , as the amount of C1INH was increased, the bradykinin generating activity of the Hageman factor fragments was progressively decreased. In order to distinguish inhibition by C1INH of the Hageman factor SL/CE NUMBER FIGURE 4 Disc gel electrophoresis of C1INH obtained by QAE Sephadex (Fig. 2) , SP Sephadex, Sephadex G-200 (Fig. 3) , and Sephadex G-150 chromatography.
fragments from direct inhibition of kallikrein, the Hageman factor fragments were incubated with C1INH (1,000 U/ml) for varying time intervals before introduction into fresh plasma. No inhibition of bradykinin generation was observed when the Hageman factor fragments and C1INH were preincubated for up to 2 min, the time interval subsequently used to assess the bradykinin generating capacity of the Hageman factor fragments in fresh plasma. After 2 min of preincubation of the fragments with C1INH, a progressive decrease in the capacity of the fragments to generate bradykinin from fresh plasma was observed (Fig. 6 ). These kinetic studies reveal that the effect of C1INH is on the Hageman factor fragments and not upon kallikrein generated.
250 IAI of Hageman factor fragments were incubated with either 250 Al of C1INH (10, prealbumin fragments (mol wt = 32,500) was utilized.
25 1ul of twofold falling dilutions of C1INH (50,000 U/ ml) were incubated for 80 min at 370C with 25 1 of Hageman factor fragment and the correction of the PTT of Hageman factor-deficient plasma determined. As shown in Fig. 8 , as the concentration of the C1INH increased, there was progressive inhibition of the coagulant activity of the Hageman factor fragment. A time-course of inhibition of the coagulant activity of the Hageman factor fragment by C1INH was studied as follows. 125 ul of Hageman factor fragment were incubated with either 125 A1 of C1INH at a concentration of 50,000 U/ml in phosphate-buffered saline pH 7.8 or in buffer alone at 370C. 50 14 samples of each mixture were then removed at designated intervals, and the ability to correct the PTT of Hageman factor-deficient plasma determined. Addition of kaolin did not lead to further activation or a decrease in PTT, as the material was completely active. No inhibition of the Hageman factor fragments occurred at 0 time, while inhibition was marked by 5 min and tended to reach a plateau after 15 min of interaction of C1INH with Hageman factor fragment (Fig. 9 ). This experiment indicates that the effect of C1INH is on the Hageman factor fragment and not upon the PTA generated or later clotting factors.
ClINH consumption
In order to ascertain whether the inhibition of the Hageman factor fragments by C1INH results in consumption of CiINH, residual C1INH was measured by its ability to inhibit Cl. 75 Al of an 80,000 mol wt Hageman factor fragment preparation undiluted and diluted 1: 2 with phosphate-buffered saline pH 7.8 were incubated with either 75 Al of C1INH (5,000 U/ml) or buffer alone at 37'C for 30 min. These mixtures were then examined for their prekallikrein and pre-PTA activating ability using fresh plasma and Hageman factordeficient plasma, respectively, as described above. The C1INH inhibited 100% of the kinin generating activity and 50% of the coagulant activity in the undiluted preparation. In addition, 75 Al of C1INH were incubated with 75 Al of a partially purified preparation of kallikrein, and 10 Al of the mixture were examined for their ability to generate bradykinin from 200 Al of heatinactivated plasma, using a 2 min incubation; the kallikrein was 90% inhibited. As shown in Fig. 10 , incubation of C1INH with either the undiluted Hageman factor fragment or Hageman factor fragment diluted 1:2 did not change the C1INH titer even though the kinin generating and coagulant ability of the fragments was markedly reduced. The partially purified kallikrein preparation produced a decrease in the C1INH titer from 4,700 to 600 U/ml.
The effect of increasing the ratio of Hageman factor fragments to C1INH was examined by incubating 10, 20, (Figs. 10 and 11 ). The functional integrity of the inhibitor after interaction with the 80,000 purified C1INH (Fig. 4) was shown to inhibit mol wt Hageman factor fragment was established by its city of active Hageman factor fragments to action in interfering with the hemolytic titration of Cf.
cinin generation, fibrinolysis, and coagulation. Even though the C1INH did not appear to be consumed MH had been previously recognized to inhibit when the prealbumin fragments were blocked, the frag-(10-12), plasmin (11) , and PTA (13) , it ments themselves could no longer be recovered either ntial to distinguish an action at these points functionally or as a protein on disc gel electrophoretic effect of the CiINH on the Hageman factor analysis of the reaction mixture (Fig. 7) 
